A new class of immune peptides is emerging as a potential tool for extending healthspan and fighting age-related decline, with one compound already approved internationally despite remaining unavailable in the US. These small proteins, derived from your thymus gland or mitochondria, work through distinct biological pathways to modulate immunity, protect cells from damage, and mimic the metabolic benefits of exercise. While most remain in early research stages, thymosin alpha-1 has accumulated decades of clinical evidence, approved in over 35 countries as Zadaxin for hepatitis B and as an immune adjuvant .

What Are Immune and Longevity Peptides, and How Do They Work?

Immune and longevity peptides represent a diverse group of compounds that operate through different biological systems. Some enhance your adaptive immune system, the part of your immunity that learns and remembers threats. Others activate your innate immune system, your body's first line of defense against pathogens. A third category consists of mitochondrial-derived peptides, small proteins encoded within your cell's energy factories that communicate your cells' health status back to the rest of your body .

The four peptides receiving the most research attention each take a different approach to supporting longevity and health. Thymosin alpha-1 is a 28-amino acid peptide naturally produced by your thymus gland, a small organ behind your breastbone that shrinks with age. LL-37 is a human antimicrobial peptide that forms part of your innate immune defense. Humanin and MOTS-c are mitochondrial-derived peptides that protect cells from damage and regulate metabolism .

Which Peptide Has the Strongest Evidence Behind It?

Thymosin alpha-1, marketed internationally as Zadaxin, stands out as the most clinically established peptide in this category. It was first isolated in the 1970s by Dr. Allan Goldstein at George Washington University from thymosin fraction 5, a partially purified preparation of bovine thymus. The synthetic version was later developed and marketed by SciClone Pharmaceuticals .

The peptide works by promoting T-cell maturation, enhancing dendritic cell activation through immune signaling pathways, and increasing natural killer cell cytotoxicity. These mechanisms translate into real clinical benefits. Multiple randomized controlled trials demonstrate improved viral clearance and seroconversion rates in hepatitis B patients when thymosin alpha-1 is used alone or combined with interferon-alpha. Studies in hepatitis C show improved sustained virological response rates when combined with interferon-based regimens .

Beyond viral hepatitis, thymosin alpha-1 has been studied in several age-related and immunocompromised conditions. Clinical trials in hepatocellular carcinoma, melanoma, and non-small cell lung cancer report improved immune parameters and some survival benefit when used as an adjunct to chemotherapy or immunotherapy. Studies in severe sepsis patients report reduced mortality, attributed to immune reconstitution during the immunosuppressive phase of sepsis. During the COVID-19 pandemic, several studies evaluated thymosin alpha-1 for severe COVID-19, with some reporting improved lymphocyte counts and clinical outcomes, though results were mixed .

How Do the Other Three Peptides Compare in Development Stage?

The remaining three peptides are at earlier stages of development, with significantly less human evidence. LL-37, a human cathelicidin antimicrobial peptide, has limited human clinical data from Phase I and II trials in wound healing and melanoma. The peptide demonstrates broad antimicrobial and antifungal activity and may support wound healing and infection clearance, but safety data remains limited .

Humanin and MOTS-c are primarily in preclinical research stages, meaning most evidence comes from laboratory and animal studies rather than human trials. Humanin is a mitochondrial-derived peptide with cytoprotective properties, theoretically offering neuroprotection and cell survival benefits associated with reduced age-related disease risk. However, no proven therapeutic effects in humans have been demonstrated yet. MOTS-c, another mitochondrial-derived peptide, functions as an exercise mimetic, activating AMPK (a cellular energy sensor), enhancing glucose metabolism, and regulating nuclear gene expression. Research suggests potential benefits in obesity, type 2 diabetes, and aging, but human intervention trials are absent .

What Are the Key Differences Between These Four Peptides?

• Thymosin Alpha-1: A 28-amino acid thymic peptide that modulates adaptive immunity through T-cell maturation and dendritic cell activation, with multiple Phase II and III trials and approval in 35+ countries as Zadaxin, costing approximately $200 to $500 per month.
• LL-37: A 37-amino acid cathelicidin that provides innate antimicrobial defense through direct antimicrobial action and immune cell recruitment, currently in Phase I and II trials for wound healing and melanoma, with limited safety data and costs ranging from $150 to $400.
• Humanin: A 16-amino acid mitochondrial-derived peptide offering cytoprotection and anti-apoptosis benefits by binding IGFBP-3 and BAX proteins, remaining in preclinical research with no human safety data available and costs between $200 and $500.
• MOTS-c: A 16-amino acid mitochondrial-derived peptide functioning as an exercise mimetic by activating AMPK and regulating glucose metabolism, primarily in preclinical research with one human exercise study, costing $60 to $150 per vial.

What Conditions Have These Peptides Been Studied For?

Thymosin alpha-1 has the broadest clinical application history. Beyond its primary indication in hepatitis B and C, it has been studied in HIV as an adjunct to antiretroviral therapy for CD4+ T-cell recovery, in cancer as an immune adjuvant, in sepsis for mortality reduction, and in COVID-19 for severe disease management. It has also been investigated as a vaccine adjuvant to enhance immune responses to influenza .

LL-37 research has focused on infections, wound healing, inflammatory skin conditions, and cystic fibrosis. Humanin studies have targeted Alzheimer's disease, cardiovascular disease, diabetes, and general aging processes. MOTS-c research has concentrated on obesity, type 2 diabetes, exercise physiology, and aging .

How to Understand the Evidence Levels for Each Peptide

• Clinical Approval Status: Thymosin alpha-1 is the only peptide with regulatory approval, available as Zadaxin in 35+ countries including Europe, Asia, and Latin America, though not yet approved by the FDA in the United States.
• Human Trial Data: Thymosin alpha-1 has multiple Phase II and III randomized controlled trials with published results, while LL-37 has early Phase I and II human trials, and Humanin and MOTS-c rely primarily on preclinical animal and laboratory research.
• Safety Profile: Thymosin alpha-1 is generally well-tolerated with mild side effects including injection site reactions and occasional flu-like symptoms, while LL-37 has limited safety data with possible injection site pain and inflammatory flares, and Humanin and MOTS-c have no human safety data available.

The regulatory landscape reflects this evidence hierarchy. Thymosin alpha-1 is approved as a medication in over 35 countries, making it the only peptide in this category with established clinical use outside research settings. LL-37 remains investigational with no approvals. Humanin and MOTS-c are in preclinical research stages with no approved clinical applications .

For individuals interested in longevity research, thymosin alpha-1 represents the most evidence-backed option among immune peptides, though its unavailability in the US limits access for American patients. The other three peptides represent promising research directions but require additional human studies before clinical recommendations can be made. Anyone considering peptide therapies should consult with a qualified healthcare provider, as none of these compounds are FDA-approved and their long-term effects in humans remain incompletely understood .